Thus, we herein attempted to confirm this hypothesis via in vivo and in vitro experiments in a mouse model of LPS-induced ALI and for the first time found that glibenclamide alleviated the development of LPS-induced ALI in a mouse model via inhibiting the NLRP3/Caspase-1/IL-1β signaling pathway, which might provide a new strategy for the treatment of LPS-induced ALI. This evidence concerns the gene CASP1 and acute respiratory distress syndrome.